share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Borgeson Blake

SEC ·  Aug 9 05:25
Summary by Futu AI
On August 6, 2024, Blake Borgeson, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of the company's Class A Common Stock. The transaction was executed on the open market at a price of $6.8213 per share, resulting in a total sale value of approximately $78,083.42. Following the sale, Borgeson directly holds a total of 7,144,216 shares in the company. The sale reflects a direct ownership transaction and is part of Borgeson's regular stock trading activities.
On August 6, 2024, Blake Borgeson, associated with Recursion Pharmaceuticals, Inc. [RXRX], completed a sale of 11,447 shares of the company's Class A Common Stock. The transaction was executed on the open market at a price of $6.8213 per share, resulting in a total sale value of approximately $78,083.42. Following the sale, Borgeson directly holds a total of 7,144,216 shares in the company. The sale reflects a direct ownership transaction and is part of Borgeson's regular stock trading activities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.